189 related articles for article (PubMed ID: 29393485)
1. Early changes in quasispecies variant after antiviral therapy for chronic hepatitis B.
Liang Y; Yano Y; Putri WA; Mardian Y; Okada R; Tanahashi T; Murakami Y; Hayashi Y
Mol Med Rep; 2018 Apr; 17(4):5528-5537. PubMed ID: 29393485
[TBL] [Abstract][Full Text] [Related]
2. Kinetics of hepatitis B surface antigen quasispecies during REP 2139-Ca therapy in HBeAg-positive chronic HBV infection.
Usman Z; Mijočević H; Karimzadeh H; Däumer M; Al-Mathab M; Bazinet M; Frishman D; Vaillant A; Roggendorf M
J Viral Hepat; 2019 Dec; 26(12):1454-1464. PubMed ID: 31323705
[TBL] [Abstract][Full Text] [Related]
3. Quasispecies dynamics in main core epitopes of hepatitis B virus by ultra-deep-pyrosequencing.
Homs M; Buti M; Tabernero D; Quer J; Sanchez A; Corral N; Esteban R; Rodriguez-Frias F
World J Gastroenterol; 2012 Nov; 18(42):6096-105. PubMed ID: 23155338
[TBL] [Abstract][Full Text] [Related]
4. Higher detection rates of amino acid substitutions in HBV reverse transcriptase/surface protein overlapping sequence is correlated with lower serum HBV DNA and HBsAg levels in HBeAg-positive chronic hepatitis B patients with subgenotype B2.
Su M; Xiang K; Li Y; Li Y; Deng J; Xu X; Yan L; Zhuang H; Li T
Infect Genet Evol; 2016 Jun; 40():275-281. PubMed ID: 27006281
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of hepatitis B antiviral drug resistance variants in North American patients with chronic hepatitis B not receiving antiviral treatment.
Lok AS; Ganova-Raeva L; Cloonan Y; Punkova L; Lin HS; Lee WM; Ghany MG;
J Viral Hepat; 2017 Nov; 24(11):1032-1042. PubMed ID: 28581155
[TBL] [Abstract][Full Text] [Related]
6. Different Variants in Reverse Transcriptase Domain Determined by Ultra-deep Sequencing in Treatment-naïve and Treated Indonesian Patients Infected with Hepatitis B Virus.
Wasityastuti W; Yano Y; Widasari DI; Yamani LN; Ratnasari N; Heriyanto DS; Okada R; Tanahashi T; Murakami Y; Azuma T; Hayashi Y
Kobe J Med Sci; 2016 Jun; 62(1):E1-8. PubMed ID: 27492206
[TBL] [Abstract][Full Text] [Related]
7. The Impact of HBV Quasispecies Features on Immune Status in HBsAg+/HBsAb+ Patients With HBV Genotype C Using Next-Generation Sequencing.
Wang Y; Xiao X; Chen S; Huang C; Zhou J; Dai E; Li Y; Liu L; Huang X; Gao Z; Wu C; Fang M; Gao C
Front Immunol; 2021; 12():775461. PubMed ID: 34899733
[TBL] [Abstract][Full Text] [Related]
8. Naturally occurring deletion/insertion mutations within HBV whole genome sequences in HBeAg-positive chronic hepatitis B patients are correlated with baseline serum HBsAg and HBeAg levels and might predict a shorter interval to HBeAg loss and seroconversion during antiviral treatment.
Hao R; Xiang K; Peng Y; Hou J; Sun J; Li Y; Su M; Yan L; Zhuang H; Li T
Infect Genet Evol; 2015 Jul; 33():261-8. PubMed ID: 25976382
[TBL] [Abstract][Full Text] [Related]
9. Ultra-deep pyrosequencing detects conserved genomic sites and quantifies linkage of drug-resistant amino acid changes in the hepatitis B virus genome.
Rodriguez-Frías F; Tabernero D; Quer J; Esteban JI; Ortega I; Domingo E; Cubero M; Camós S; Ferrer-Costa C; Sánchez A; Jardí R; Schaper M; Homs M; Garcia-Cehic D; Guardia J; Esteban R; Buti M
PLoS One; 2012; 7(5):e37874. PubMed ID: 22666402
[TBL] [Abstract][Full Text] [Related]
10. Multiple Hepatitis B Virus (HBV) Quasispecies and Immune-Escape Mutations Are Present in HBV Surface Antigen and Reverse Transcriptase of Patients With Acute Hepatitis B.
Aragri M; Alteri C; Battisti A; Di Carlo D; Minichini C; Sagnelli C; Bellocchi MC; Pisaturo MA; Starace M; Armenia D; Carioti L; Pollicita M; Salpini R; Sagnelli E; Perno CF; Coppola N; Svicher V
J Infect Dis; 2016 Jun; 213(12):1897-905. PubMed ID: 26908731
[TBL] [Abstract][Full Text] [Related]
11. Evolutionary pattern of full hepatitis B virus genome during sequential nucleos(t)ide analog therapy.
Tang YZ; Liu L; Pan MM; Wang YM; Deng GH
Antiviral Res; 2011 Jun; 90(3):116-25. PubMed ID: 21440005
[TBL] [Abstract][Full Text] [Related]
12. Association of characteristics of HBV quasispecies with hepatitis B surface antigen seroconversion after pegylated interferon-α-2a treatment in child patients.
Yang J; Yang G; He H; Ning L; Liu Z; Fu Q; Chen H; Deng H; Wang Z; Luo K
Antivir Ther; 2018; 23(7):567-574. PubMed ID: 30095435
[TBL] [Abstract][Full Text] [Related]
13. Integration of hepatitis B virus S gene impacts on hepatitis B surface antigen levels in patients with antiviral therapy.
Hu B; Wang R; Fu J; Su M; Du M; Liu Y; Li H; Wang H; Lu F; Jiang J
J Gastroenterol Hepatol; 2018 Jul; 33(7):1389-1396. PubMed ID: 29266382
[TBL] [Abstract][Full Text] [Related]
14. New amino acid changes in drug resistance sites and HBsAg in hepatitis B virus genotype H.
Fernández-Galindo DA; Sánchez-Ávila F; Bobadilla-Morales L; Gómez-Quiróz P; Bueno-Topete M; Armendáriz-Borunda J; Sánchez-Orozco LV
J Med Virol; 2015 Jun; 87(6):985-92. PubMed ID: 25732900
[TBL] [Abstract][Full Text] [Related]
15. [Evolution of hepatitis B virus quasispecies during antiviral therapy in one chronic hepatitis B patient].
Liang PP; Guo JJ; Li QL; Luo Q; Shi XF; Huang AL
Zhonghua Gan Zang Bing Za Zhi; 2011 Jul; 19(7):516-20. PubMed ID: 22152243
[TBL] [Abstract][Full Text] [Related]
16. High prevalence of tryptophan-truncated S quasispecies in treatment-naïve chronic hepatitis B patients.
Dong H; Zhu Y; Shen Y; Xie S; He Y; Lu L
J Gen Virol; 2021 Jul; 102(7):. PubMed ID: 34292864
[TBL] [Abstract][Full Text] [Related]
17. Nucleos(t)ide analogues altered quasispecies composition of hepatitis B virus (HBV)-resistant mutations in serum HBV DNA and serum HBV RNA.
Liao H; Zhang H; Shao J; Li X; Zheng WV; Li L; Yu G; Si L; Zhou T; Yao Z; Dai J; Xu D; Cheng G; Qu J; Liu Y; Chen J; Lu F
J Med Virol; 2023 Mar; 95(3):e28612. PubMed ID: 36840474
[TBL] [Abstract][Full Text] [Related]
18. Early dynamic changes of quasispecies in the reverse transcriptase region of hepatitis B virus in telbivudine treatment.
Tang X; Huang W; Kang J; Ding K
Antiviral Res; 2021 Nov; 195():105178. PubMed ID: 34509461
[TBL] [Abstract][Full Text] [Related]
19. Dynamics of hepatitis B virus quasispecies in association with nucleos(t)ide analogue treatment determined by ultra-deep sequencing.
Nishijima N; Marusawa H; Ueda Y; Takahashi K; Nasu A; Osaki Y; Kou T; Yazumi S; Fujiwara T; Tsuchiya S; Shimizu K; Uemoto S; Chiba T
PLoS One; 2012; 7(4):e35052. PubMed ID: 22523569
[TBL] [Abstract][Full Text] [Related]
20. Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis B.
Bayliss J; Yuen L; Rosenberg G; Wong D; Littlejohn M; Jackson K; Gaggar A; Kitrinos KM; Subramanian GM; Marcellin P; Buti M; Janssen HLA; Gane E; Sozzi V; Colledge D; Hammond R; Edwards R; Locarnini S; Thompson A; Revill PA
Gut; 2017 Nov; 66(11):2013-2023. PubMed ID: 27534671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
